Delafloxacin Meglumine Patent Expiration
Delafloxacin Meglumine is used for treating acute bacterial skin infections in adults. It was first introduced by Melinta Subsidiary Corp
Delafloxacin Meglumine Patents
Given below is the list of patents protecting Delafloxacin Meglumine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Baxdela | US12036219 | Methods of treating infections in overweight and obese patients using antibiotics | Jun 02, 2034 | Melinta |
| Baxdela | US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | Feb 27, 2033 | Melinta |
| Baxdela | US12138257 | Antimicrobial compositions | May 01, 2032 | Melinta |
| Baxdela | US7728143 | Salt and crystalline forms thereof of a drug | Jun 19, 2031 | Melinta |
| Baxdela | US8497378 | Process for making quinolone compounds | Dec 28, 2029 | Melinta |
| Baxdela | USRE46617 | Process for making quinolone compounds | Dec 28, 2029 | Melinta |
| Baxdela | US8871938 | Process for making quinolone compounds | Sep 23, 2029 | Melinta |
| Baxdela | US7635773 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Melinta |
| Baxdela | US8410077 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Melinta |
| Baxdela | US9200088 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Melinta |
| Baxdela | US9750822 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Melinta |
| Baxdela | US8252813 | Salt and crystalline forms thereof of a drug | Oct 02, 2026 | Melinta |
| Baxdela | US8273892 | Salt and crystalline forms thereof of a drug | Aug 06, 2026 | Melinta |
| Baxdela | US8648093 | Salt and crystalline forms thereof of a drug | Oct 07, 2025 | Melinta |
| Baxdela | US8969569 | Salt and crystalline forms thereof of a drug | Oct 07, 2025 | Melinta |
| Baxdela | US9539250 | Salt and crystalline forms thereof of a drug | Oct 07, 2025 | Melinta |
Delafloxacin Meglumine's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List